Cantor Fitzgerald set a $20.00 target price on Impax Laboratories, Inc. (NASDAQ:IPXL) in a research note published on Wednesday, August 9th. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

IPXL has been the topic of several other reports. Vetr cut shares of Impax Laboratories from a strong-buy rating to a strong sell rating and set a $10.55 target price for the company. in a research note on Monday, May 1st. Deutsche Bank AG set a $21.00 price objective on shares of Impax Laboratories and gave the stock a buy rating in a research note on Monday, July 17th. Zacks Investment Research cut shares of Impax Laboratories from a hold rating to a strong sell rating in a research note on Monday, July 24th. Royal Bank Of Canada set a $15.00 price objective on shares of Impax Laboratories and gave the stock a hold rating in a research note on Sunday, July 16th. Finally, BidaskClub upgraded shares of Impax Laboratories from a hold rating to a buy rating in a research note on Wednesday, July 12th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $17.85.

Impax Laboratories (NASDAQ:IPXL) traded up 2.79% during trading on Wednesday, hitting $18.45. The company had a trading volume of 1,826,679 shares. The firm’s 50 day moving average is $17.60 and its 200-day moving average is $14.55. The stock’s market capitalization is $1.33 billion. Impax Laboratories has a 52-week low of $7.75 and a 52-week high of $27.29.

Impax Laboratories (NASDAQ:IPXL) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.04. The business had revenue of $202.08 million for the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The firm’s quarterly revenue was up 17.1% compared to the same quarter last year. During the same period last year, the firm posted $0.21 earnings per share. On average, equities analysts forecast that Impax Laboratories will post $0.70 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/19/impax-laboratories-inc-nasdaqipxl-given-a-20-00-price-target-by-cantor-fitzgerald-analysts-updated.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Norges Bank bought a new position in shares of Impax Laboratories during the fourth quarter valued at about $16,669,000. Quadrature Capital Ltd bought a new position in shares of Impax Laboratories during the fourth quarter valued at about $224,000. GW&K Investment Management LLC increased its position in shares of Impax Laboratories by 3.1% in the first quarter. GW&K Investment Management LLC now owns 777,095 shares of the specialty pharmaceutical company’s stock valued at $9,830,000 after buying an additional 23,142 shares during the period. Bank of Montreal Can increased its position in shares of Impax Laboratories by 60.4% in the first quarter. Bank of Montreal Can now owns 53,874 shares of the specialty pharmaceutical company’s stock valued at $681,000 after buying an additional 20,288 shares during the period. Finally, Louisiana State Employees Retirement System increased its position in shares of Impax Laboratories by 1.0% in the first quarter. Louisiana State Employees Retirement System now owns 30,000 shares of the specialty pharmaceutical company’s stock valued at $380,000 after buying an additional 300 shares during the period. Institutional investors and hedge funds own 83.57% of the company’s stock.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.